BTIG Research Reiterates Hold Rating for Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “hold” rating reiterated by analysts at BTIG Research in a report issued on Tuesday.

A number of other equities research analysts also recently weighed in on the company. SunTrust Banks set a $430.00 price objective on Regeneron Pharmaceuticals and gave the company a “hold” rating in a report on Friday, February 9th. Morgan Stanley lifted their price objective on Regeneron Pharmaceuticals from $401.00 to $415.00 and gave the company an “equal weight” rating in a report on Friday, February 9th. Leerink Swann decreased their price objective on Regeneron Pharmaceuticals from $568.00 to $502.00 and set an “outperform” rating on the stock in a report on Friday, February 9th. Robert W. Baird raised Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating in a report on Friday, February 9th. They noted that the move was a valuation call. Finally, Guggenheim set a $530.00 price objective on Regeneron Pharmaceuticals and gave the company a “buy” rating in a report on Friday, February 9th. Four analysts have rated the stock with a sell rating, fourteen have given a hold rating and eleven have given a buy rating to the company. Regeneron Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $463.19.

Shares of Regeneron Pharmaceuticals (NASDAQ REGN) opened at $330.69 on Tuesday. Regeneron Pharmaceuticals has a 1 year low of $313.53 and a 1 year high of $543.55. The firm has a market capitalization of $35,530.00, a PE ratio of 32.04, a P/E/G ratio of 1.39 and a beta of 1.47. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.18 and a current ratio of 3.82.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share for the quarter, topping analysts’ consensus estimates of $4.18 by $1.05. The business had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.50 billion. Regeneron Pharmaceuticals had a return on equity of 28.48% and a net margin of 20.41%. The firm’s revenue for the quarter was up 28.9% compared to the same quarter last year. During the same period last year, the business earned $3.04 earnings per share. analysts anticipate that Regeneron Pharmaceuticals will post 14.13 EPS for the current year.

In other news, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $325.60, for a total value of $325,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 10.80% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Shell Asset Management Co. raised its position in Regeneron Pharmaceuticals by 24.1% in the 3rd quarter. Shell Asset Management Co. now owns 15,435 shares of the biopharmaceutical company’s stock worth $5,565,000 after purchasing an additional 2,999 shares during the last quarter. DnB Asset Management AS bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $9,136,000. Northpointe Capital LLC bought a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $2,089,000. Cubist Systematic Strategies LLC raised its position in Regeneron Pharmaceuticals by 176.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 671 shares of the biopharmaceutical company’s stock worth $330,000 after purchasing an additional 428 shares during the last quarter. Finally, Griffin Asset Management Inc. bought a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $1,579,000. Hedge funds and other institutional investors own 65.89% of the company’s stock.

WARNING: “BTIG Research Reiterates Hold Rating for Regeneron Pharmaceuticals (REGN)” was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.chaffeybreeze.com/2018/02/15/btig-research-reiterates-hold-rating-for-regeneron-pharmaceuticals-regn.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply